J'achète l'étude complète
Synthèse
The global market for aesthetic surgery and medicine, valued at $127.1 billion in 2023, is set to grow substantially, aiming to reach $332.1 billion. This growth trajectory has been driven by technological innovations in aesthetic devices, increasing non-invasive treatment options and growing acceptance of aesthetic procedures, particularly in the Asia-Pacific region, which has seen annual growth of over 10%.
The market remains dominated by the United States, which accounted for 45% of global sales by value in 2020, followed by Europe, Asia-Pacific and Latin America. Non-surgical procedures such as hyaluronic acid and botulinum toxin injections have surged. Socio-demographic factors such as an ageing population, changing beauty ideals influenced by social media and new consumer demographics, particularly men and young people, have all contributed to strong market growth from 2020 onwards.
Navigating the trends and growth dynamics of the French beauty market
In recent years, the French aesthetics market has experienced remarkable growth. Factors contributing to this growth include changing societal attitudes towards physical appearance, an ageing population that increasingly wishes to rejuvenate its appearance, and technological advances in non-invasive procedures. By 2021, the market has reached a value of around 10 to 15 billion euros, and this strong expansion is expected to maintain an annual growth rate of around 10 to 20% until at least 2024. In France, more than 300,000 cosmetic surgery operations and over 400,000 aesthetic medicine procedures were realized in 2022, testifying to the growing acceptance and search for aesthetic improvements among the French population.
Aesthetic surgery has seen an increase of around 10-15% in the space of a year, with the number of people undergoing procedures reaching around 1-2 million. This increase can be partly attributed to the aging of the population, with people aged 75 and over making up around 5-10% of the population by 2023, a figure that is expected to double by 2070. Demand for aesthetic services in France is strongly influenced by the fact that the boundary between aesthetics and medicine is blurring, as more and more people opt for less invasive procedures that promise temporary but immediate results. Among these procedures, hyaluronic acid and botulinum toxin injections are particularly important, as the country has seen a trend towards aesthetic medicine, which now accounts for around 50% of the market for aesthetic procedures.
Not to be overlooked is the influence of social media on younger generations, which has played a key role in changing ideals and perceptions of beauty. It has been observed that people aged between 18 and 25 are now more inclined to resort to cosmetic surgery than those aged between 50 and 60. This change is probably due to the desire to emulate the filtered perfection popularized by social media platforms.
In addition, advances in the production of medical and cosmetic surgery equipment have strengthened the structure of the market. France boasts a number of specialist manufacturers who contribute to a complex manufacturing chain in the cosmetic surgery and cosmeceutical segments. In general, production is led by international conglomerates, but some French companies have carved out a niche for themselves in injectables and cosmetics, maintaining production sites in the country. As the market evolves, so does the distribution framework, with a diverse range of distribution channels enjoying renewed activity.
Key players in the French aesthetic medicine and surgery market
The French market for aesthetic medicine and surgery is a dynamic, fast-growing sector, characterized by the presence of a number of established, leading players. Companies ranging from specialist equipment manufacturers to cosmetics giants and healthcare providers contribute to the bouquet of services and products that meet a wide range of consumer needs. Here's a look at the major players shaping the French market.
- Allergan: A long-standing player and leader in the field of aesthetics, Allergan is known for its wide range of products, from injectables and breast implants to energy-based devices and cosmeceuticals. With a diversified product portfolio, Allergan has consolidated its position despite regulatory hurdles such as the withdrawal of its Biocell textured breast implants from the French market.
- Eurosilicone (GC Aesthetics) and Laboratoires Sebbin: These two companies are renowned manufacturers of breast implants, supplying high-quality products to national and international markets. Thanks to the meticulous processes involved in creating these implants, they help to reinforce the confidence and reliability of aesthetic solutions.
- Laboratoires Vivacy: A major player in the injectables market, Laboratoires Vivacy specializes in aesthetic and anti-aging products, including dermal fillers, in particular hyaluronic acid.
- L'Oréal and its Cosmétique Active division: Building on its heritage in the beauty industry, L'Oréal's Cosmétique Active division, which includes Skinceuticals, Vichy and La Roche-Posay, is at the forefront of the cosmeceuticals segment. These brands combine cosmetic and therapeutic benefits to offer high-quality skincare products.
- Deleo: Representing French prowess in medical technology, Deleo has marked its presence on the world stage with its innovative energy-based aesthetic devices. Specializing in cryolipolysis devices and high-power LED lamps, Deleo testifies to French industry's ability to innovate at the cutting edge of technology.
- Merz and Galderma: Merz is known for its BoCouture product, while Galderma plays a crucial role with its botulinum toxin product Azzalure. Both companies contribute strongly to the botulinum toxin market in France, focusing on regulated aesthetic treatments.
- Syneron-Candela and Lumenis: These international players occupy a strong position in the supply of energy-based devices, which include advanced lasers and body contouring systems.
à la compréhension de ce marché
Détail du contenu
Informations
- Nombre de pages : 30 pages
- Format : Version digitale et PDF
- Dernière mise à jour : 02/10/2023
Sommaire et extraits
1 Market overview
1.1 Definitions and market overview
The aesthetic medicine and surgery market in France comprises several distinct segments[La Roche Posay; Le Figaro Santé] :
Aesthetic surgery
A speciality of plastic surgery, this technique of reshaping the body through surgical intervention corrects a morphological anomaly or the outward appearance of a patient's body. The results are radical .
Among the most common procedures are[Fashion4mec]:
- Facial surgery: cervico-facial lift, rhinosplasty (nose), blepharoplasty (eyelids).
- Breast surgery: breast augmentation, breast reduction, breast reconstruction, breast implant replacement.
- Body surgery: abdominoplasty, liposuction, lipomodelling, intimate surgery.
Aesthetic medicine
This covers all non-surgical advice, care and treatment designed to improve a patient's aesthetic appearance. Described as "non-invasive", the vast majority of procedures involve injections under the skin, for example to reduce wrinkles. The result of a procedure is temporary and reversible. Aesthetic medical procedures must therefore be repeated to maintain their benefits .
The most common procedures include[CR] :
- hyaluronic acid injection
- botulinum toxin injections
- tightening or lifting threads
- cryolipolysis (cold fat removal)
- laser hair removal
- peeling (exfoliation/dermo-epidermal stimulation)
- hair transplant
Cosmeceuticals
Halfway between cosmetics and drugs, cosmeceuticals contain active ingredients for specific dermatological treatments (wrinkles, dark circles, etc.). Cosmeceuticals are most frequently used to correct skin aging, although their efficacy has yet to be proven.
The first breast augmentations were performed in the 1950s/1960s, just as lasers were making their appearance in dermatology. Later, in the 80s, Dr Gérard Yllouz revolutionized cosmetic surgery by inventing liposuction. Finally, in the 90s and 2000s, aesthetic medicine emerged with the development of botox and hyaluronic acid.[Reau]
The global market for aesthetic surgery and medicine is booming, driven in particular by the dynamism of the Asian regions, which are currently the main focus of global demand. However, the market is still largely dominated by the United States and Brazil, and is valued at $127.1 billion in 2023, rising at a CAGR of14.7% from 2023 to 2030, to reach $332.1 billion. This growth is due in part to the boom in injectable substances, to the renewal of equipment and technologies required for operations, but also to the dual context of an ageing population and growing acceptance of cosmetic surgery. [GV]
The French market is also growing, thanks in particular to the growing popularity of aesthetic medicine methods, which straddle the line between medical treatment and simple cosmetic surgery.the French market is also growing, thanks in particular to the growing popularity of aesthetic medicine methods, which straddle the line between medical treatment and simple aesthetic procedures, to the detriment of in-clinic surgical procedures whose popularity has been affected by a number of scandals. The French aesthetics market will be worth 12 billion euros by 2021, with average annual growth of 15% from 2018 until at least 2024. [Clinique des Champs Elysées]
According to Le Figaro,more than 320,000 cosmetic surgery and 420,000 aesthetic medicine procedures were carried out in the country in 2022.As a result, the number of French people who have already had cosmetic surgery is estimated to have risen by 13% in one year, to 1.4 million.
Lastly, the legal framework plays a key role in regulating the market and authorizing certain practices. It therefore plays a decisive role in understanding market supply and major market dynamics [France Tv].
1.2 A fast-growing global market
The global market for aesthetic surgery and medicine is valued at $***.* billion in ****, and is expected to grow at a CAGR of **.*% from **** to ****, reaching $***.* billion. Innovation in aesthetic devices over the past decade has driven growth in demand for aesthetic treatments.
The introduction of technically advanced products, such as non-invasive ...
1.3 The French market
The French aesthetics market will be worth ** billion euros by ****, with average annual growth of **% from **** until at least ****. [***]
According to Le Figaro,more than ***,*** cosmetic surgery and ***,*** aesthetic medicine procedures were carried out in the country in ****.The number of French people who have already had cosmetic surgery is estimated ...
1.4 The phenomenon of patients fleeing abroad
Mexico, Turkey and Colombia recorded the highest proportion of foreign patients: **.*%, **.*% and **.*% respectively in ****. Thailand, which ranked first in ****, was fourth, with **.*%. Figures for **** are not revealed by ISAPS, but these four countries remain those with the highest proportion of foreign patients. [***]
Ranking of countries with the most foreign patients for ...
2 Demand analysis
2.1 Socio-demographic factors driving market growth
In France, demand in the aesthetics market has been growing steadily for several decades, thanks to various socio-demographic factors such as an aging population, the growing importance of physical appearance in French society, a steadily increasing female population, and the expansion of the market to include men and young people.these ...
2.2 Demand driven by a small part of the population
However, demand is very intensely concentrated in a small proportion of the population that carries the aesthetic market. Indeed, as shown in the graph below, which incorporates the results of an IFOP survey carried out in June **** in France, the proportion of people considering cosmetic surgery or medicine was already very ...
2.3 The most popular operations
The International Public Sector Accounting Standards (***) has released its **** report on the global aesthetic care business. In order to obtain more recent and accurate data on certain products, we will study the data in this report.
Breakdown of most popular surgical procedures World, ****, as % of total Source: ****
In terms of aesthetic ...
3 Market structure
3.1 A market structured around equipment manufacturers and practitioners
There are two main types of players in the aesthetic medicine and surgery market: upstream manufacturers of equipment for aesthetic purposes, and downstream practitioners or treatment establishments.
*) Equipment manufacturers
The French market for manufacturers is characterized by a high degree of specialization, due to the demanding technology and cost of ...
3.2 Production of medical and cosmetic surgery equipment
The production of aesthetic equipment includes breast prostheses, injectables, equipment and cosmeceuticals. As the aesthetic market requires high entry costs and cutting-edge technology, most manufacturers specialize in one of these segments.
As the main market players are international groups, the majority of production sites are located abroad, with the exception of ...
3.3 A trend towards diversification
Players in the distribution market
The aesthetic products distribution market comprises three main types of player: the group in charge of production, a subsidiary of the group specialized in distribution, and finally a wholesaler specialized in the distribution of aesthetic medicine and surgery products.
The integrated model, in which the company ...
3.4 Multi-channel distribution and growing consumer autonomy
Thegrowth of various distribution channels has prompted manufacturers to gear their distribution towards a multi-channel strategy. Today, the main distribution channels on the rise are selective perfumeries, web merchants, mail order and large-scale distribution specialized in home appliances. Talika's home devices, for example, have been sold since **** at Marionnaud and in ...
4 Offer analysis
4.1 Typology of aesthetic medicine services
Aesthetic medicine
In France, aesthetic medicine was mainly composed of injection procedures (***) [***]. The census of procedures carried out in France dates from ****, but there have been no drastic changes since then, so the figures still make sense in ****.
Wrinkle-filling injections, on the other hand, are much less regulated, allowing over *** brands ...
4.2 Prices for aesthetic medicine services
According to the French Association of Aesthetic and Anti-Aging Medicine (***), average prices for various aesthetic medicine procedures on the silhouette by the end of **** are as follows:
Source: ****
For cosmetic surgery on the body, the results are as follows:
Source: ****
Prices for cosmetic surgery on the face and neck are as ...
5 Regulations
5.1 Regulations governing aesthetic medicine and surgery
Law no. ****-*** of March *, ****, on patients' rights and the quality of the healthcare system, also known as the Kouchner law, is partly intended to regulate the practice of aesthetic medicine and surgery. [***]
The quality and safety of care are thus ensured by :
*) Controlling surgeons' competence[***]
The practice of aesthetic ...
5.2 Even stricter regulations in the wake of the PIP scandal
The medical and cosmetic surgery market continues to grow despite the PIP affair, which began in in ****, when the prostheses were withdrawn from the market following the first case of cancer detected due to anomalies in the product. In ****, the certifying body for these prostheses, TÜV, was ordered to pay ...
Liste des graphiques
- Le marché mondial de la médecine esthétique en valeur
- Evolution du nombre d'interventions par type
- Chiffre d'affaires du marché des soins de beauté de code APE 96.02B
- Projection de population à l'horizon 2070
- Proportion des 65 ans ou plus dans la population française
Toutes nos études sont disponible en ligne et en PDF
Nous vous proposons de consulter un exemple de notre travail d'étude sur un autre marché !
Dernières actualités
Le laboratoire suisse de dermatologie Galderma entre en Bourse - 07/03/2024
- - Galderma a été fondé en 1981 par Nestlé et L'Oréal.
- - EQT a repris Galderma en 2019 et prévoit d'introduire Galderma à la Bourse de Zurich.
- - Galderma vise une levée de capital d'environ 2,3 milliards de dollars
- - Galderma est basé à Zoug, en Suisse, et emploie 6.500 personnes au niveau mondial, dont 500 en France.
- - Galderma se présente comme un « pur player » de la dermatologie, avec sa marque de cosmétiques Cetaphil.
- - Les ventes de Cetaphil s'élèveraient à plus d'un milliard de dollars en 2023, soit un quart du chiffre d'affaires de Galderma pour la même année (4.1 milliards de dollars).
- - EQT a racheté Galderma à Nestlé en 2019 pour 10,2 milliards de francs suisses (10,6 milliards d'euros).
Ce spécialiste des soins de la peau a été cofondé en 1981 par L'Oréal et Nestlé. - 06/03/2024
- Les ventes de Galderma ont dépassé pour la première fois les 4 milliards de dollars.
- Galderma a été créé en 1981 par L'Oréal et Nestlé.
- En 2014, Nestlé est devenu le seul actionnaire de Galderma. À cette époque, Galderma réalisait un chiffre d'affaires de 1,6 milliard d'euros.
- En 2019, un consortium mené par le fonds suédois EQT et une filiale du fonds souverain Abu Dhabi Investment Authority a acquis Galderma pour 9,3 milliards d'euros.
- Le chiffre d'affaires de la branche "skin health" de Nestlé était de 2,9 milliards d'euros.
- Pour 2024, Galderma prévoit une croissance de ses ventes de 7 % à 10 %.
- Galderma prévoit de lever 2,3 milliards de dollars (soit 2,1 milliards d'euros) dans le cadre de son introduction en bourse
L’impegno di Ipsen nell’area delle malattie rare - 29/02/2024
Performance e alle strategie dell'azienda biofarmaceutica Ipsen nel 2023:
- **Incremento delle vendite:** Nel 2023, Ipsen ha registrato un incremento delle vendite globali pari al 3,4% rispetto all'anno precedente.
- **Margine operativo:** L'azienda ha registrato un margine operativo del 26,1%, che evidenzia un aumento del 2% in confronto al 2022.
- **Fattori di crescita:** La crescita è stata supportata dagli asset storici dell'azienda, dai nuovi farmaci, dall’espansione della pipeline e dall’accelerazione degli investimenti in ricerca e sviluppo, particolarmente beneficiati dalle recenti acquisizioni focalizzate sull'area delle malattie rare.
- **Ingresso nel settore delle malattie rare:** Nel 2023, Ipsen ha acquisito Albireo, una società leader nello sviluppo di modulatori degli acidi biliari per il trattamento delle malattie epatiche colestatiche pediatriche e adulte, introducendo nel mercato odevixibat, il primo trattamento approvato contro la colestasi intraepatica familiare progressiva (Pfic).
- **Piani futuri:** Per il 2024, Ipsen prevede il lancio mondiale di quattro terapie innovative e l'ampliamento della pipeline, supportato da una strategia di innovazione esterna nelle sue tre aree terapeutiche principali.
- **Impegno nel campo delle malattie rare:** Con nuovi sviluppi come odevixibat e una pipeline in evoluzione, Ipsen segna il suo ingresso ufficiale nel settore delle malattie rare, puntando a portare innovazioni terapeutiche che possano cambiare il decorso delle malattie, con un focus su farmaci con nuovi meccanismi d’azione.
En transition, Ipsen assure sa croissance mais son profit est en berne - 09/02/2024
- - Les ventes du médicament somatuline d'Ipsen sont de 1,07 milliard d'euros, en recul de 12,5 %.
- - Ce médicament représente désormais 34 % des ventes totales du groupe, contre 40 % précédemment.
- - Les ventes de l'anticancéreux cabometyx ont augmenté de 19 % pour atteindre 535 millions d'euros.
- - Les ventes du pôle oncologie ont diminué de 1,2 % pour s'établir à 2,3 milliards d'euros.
- - Le chiffre d'affaires total d'Ipsen a progressé de 3,4 % pour atteindre 3,1 milliards d'euros.
- - Le nouveau médicament Bylvay d'Albireo a réalisé 74 millions d'euros de ventes.
- - Les ventes de la toxine botulique, Dysport, ont augmenté de 9 % pour atteindre 649 millions d'euros en 2023.
- - Le résultat net a baissé de 12,7 % pour atteindre un peu moins de 763 millions d'euros.
Ipsen prévoit une forte croissance des ventes - 08/12/2023
- Ipsen est le troisième laboratoire pharmaceutique français.
- Ipsen est un des principaux concurrents de la marque Botox d'Allergan.
- Ipsen prévoit une croissance moyenne de ses ventes d'au moins 7 % par an pour les quatre prochaines années.
Botox : la toxine botulique embellit les comptes de la pharmacie - 02/08/2023
- Les Etats-Unis représentent la moitié du marché mondial de la toxine botulique.
- Le Botox a représenté l'an dernier pour AbbVie 5,2 milliards de dollars de ventes mondiales, à parts égales entre l'esthétique (+21 % hors effet de change) et le thérapeutique (+13 %).
- Aux Etats-Unis, Dysport (Ipsen) n'a que 5 % du marché du thérapeutique, contre 30 % en France.
- Dans l'esthétique aux Etats-Unis, Ipsen a une part éstimée de 20 % à 25 %.
- Sur 1,5 milliard d'euros de chiffre d'affaires semestriel (+7 %) du laboratoire français Ipsen, 319 millions (+32 %) viennent de la toxine botulique vendue en thérapeutique et, dans certains pays, en esthétique.
- Botox détient 40 % à 50 % du marché thérapeutique en France, contre 30 % pour Ipsen.
Entreprises citées dans cette étude
Cette étude contient un panorama complet des entreprises du marché avec les derniers chiffres et actualités de chaque entreprise :
Choisir cette étude c'est :
Accéder à plus de 35 heures de travail
Nos études sont le résultat de plus de 35 heures de recherches et d'analyses. Utiliser nos études vous permet de consacrer plus de temps et de valeur ajoutée à vos projets.
Profiter de 6 années d'expérience et de plus de 1500 études sectorielles déjà produites
Notre expertise nous permet de produire des études complètes dans tous les secteurs, y compris des marchés de niche ou naissants.
Notre savoir-faire et notre méthodologie nous permet de produire des études avec un rapport qualité-prix unique
Accéder à plusieurs milliers d'articles et données payantes
Businesscoot a accès à l'ensemble de la presse économique payante ainsi qu'à des bases de données exclusives pour réaliser ses études de marché (+ 30 000 articles et sources privées).
Afin d'enrichir nos études, nos analystes utilisent également des indicateurs web (semrush, trends…) pour identifier les tendances sur un marché et les stratégies des entreprises. (Consulter nos sources payantes)
Un accompagnement garanti après votre achat
Une équipe dédiée au service après-vente, pour vous garantir un niveau de satisfaction élevé. (+33) 9 70 46 55 00
Un format digital pensé pour nos utilisateurs
Vous accédez à un PDF mais aussi à une version digitale pensée pour nos clients. Cette version vous permet d’accéder aux sources, aux données au format Excel et aux graphiques. Le contenu de l'étude peut ainsi être facilement récupéré et adapté pour vos supports.
Nos offres :
the aesthetic medicine market | France
- Quels sont les chiffres sur la taille et la croissance du marché ?
- Quels leviers tirent la croissance du marché et leur évolution ?
- Quel est le positionnement des entreprises sur la chaine de valeur ?
- Comment se différencient les entreprises du marché ?
- Données issues de plusieurs dizaines de bases de données
Pack 5 études (-15%) France
- 5 études au prix de 75,6€HT par étude à choisir parmi nos 800 titres sur le catalogue France pendant 12 mois
- Conservez -15% sur les études supplémentaires achetées
- Choisissez le remboursement des crédits non consommés au terme des 12 mois (durée du pack)
Consultez les conditions du pack et de remboursement des crédits non consommés.
- 03/04/2024 - Mise à jour des données financières de l'entreprise Allergan plc
- 03/03/2024 - Mise à jour des données financières de l'entreprise Deleo
- 03/03/2024 - Mise à jour des données financières de l'entreprise Candela Medical
- 03/03/2024 - Mise à jour des données financières de l'entreprise Arion
- 03/03/2024 - Mise à jour des données financières de l'entreprise Merz Pharmaceuticals
- 03/03/2024 - Mise à jour des données financières de l'entreprise Filorga Cosmétiques (Colgate Palmolive)
- 03/03/2024 - Mise à jour des données financières de l'entreprise Lierac (Laboratoire Native)
- 03/03/2024 - Mise à jour des données financières de l'entreprise Laboratoires Sebbin
- 01/03/2024 - Mise à jour des données financières de l'entreprise La Roche-Posay
- 01/03/2024 - Mise à jour des données financières de l'entreprise Galderma
- 02/01/2024 - Mise à jour des données financières de l'entreprise Allergan plc
- 02/12/2023 - Mise à jour des données financières de l'entreprise Deleo
- 02/12/2023 - Mise à jour des données financières de l'entreprise Candela Medical
- 02/12/2023 - Mise à jour des données financières de l'entreprise Arion
- 02/12/2023 - Mise à jour des données financières de l'entreprise Laboratoires Sebbin
- 02/12/2023 - Mise à jour des données financières de l'entreprise Lierac (Laboratoire Native)
- 02/12/2023 - Mise à jour des données financières de l'entreprise Filorga Cosmétiques (Colgate Palmolive)
- 02/12/2023 - Mise à jour des données financières de l'entreprise Merz Pharmaceuticals
- 04/11/2023 - Mise à jour des données financières de l'entreprise La Roche-Posay
- 04/11/2023 - Mise à jour des données financières de l'entreprise Galderma
- 01/10/2023 - Mise à jour des données financières de l'entreprise Allergan plc
- 01/09/2023 - Mise à jour des données financières de l'entreprise Deleo
- 01/09/2023 - Mise à jour des données financières de l'entreprise Candela Medical
- 01/09/2023 - Mise à jour des données financières de l'entreprise Arion
- 01/09/2023 - Mise à jour des données financières de l'entreprise Laboratoires Sebbin
- 01/09/2023 - Mise à jour des données financières de l'entreprise Lierac (Laboratoire Native)
- 01/09/2023 - Mise à jour des données financières de l'entreprise Filorga Cosmétiques (Colgate Palmolive)
- 01/09/2023 - Mise à jour des données financières de l'entreprise Merz Pharmaceuticals
- 03/08/2023 - Mise à jour des données financières de l'entreprise La Roche-Posay
- 03/08/2023 - Mise à jour des données financières de l'entreprise Galderma
- 03/07/2023 - Ajout des informations de l'entreprise Skincareagency
- 14/06/2023 - Mise à jour des données financières de l'entreprise Allergan plc
- 19/05/2023 - Ajout des informations de l'entreprise Maison Lutetia
- 19/05/2023 - Mise à jour des données financières de l'entreprise Deleo
- 19/05/2023 - Mise à jour des données financières de l'entreprise Candela Medical
- 19/05/2023 - Mise à jour des données financières de l'entreprise Arion
- 19/05/2023 - Mise à jour des données financières de l'entreprise Laboratoires Sebbin
- 19/05/2023 - Mise à jour des données financières de l'entreprise Lierac (Ales Groupe)
- 19/05/2023 - Mise à jour des données financières de l'entreprise Filorga Cosmétiques (Colgate Palmolive)
- 19/05/2023 - Mise à jour des données financières de l'entreprise Merz Pharmaceuticals
- 16/04/2023 - Mise à jour des données financières de l'entreprise La Roche-Posay
- 16/04/2023 - Mise à jour des données financières de l'entreprise Galderma
- 21/02/2023 - Mise à jour des données financières de l'entreprise Ipsen
- 18/02/2023 - Mise à jour des données financières de l'entreprise Deleo
- 18/02/2023 - Mise à jour des données financières de l'entreprise Candela Medical
- 18/02/2023 - Mise à jour des données financières de l'entreprise Arion
- 18/02/2023 - Mise à jour des données financières de l'entreprise Filorga Cosmétiques (Colgate Palmolive)
- 18/02/2023 - Mise à jour des données financières de l'entreprise Lierac (Ales Groupe)
- 18/02/2023 - Mise à jour des données financières de l'entreprise Laboratoires Sebbin
- 18/02/2023 - Mise à jour des données financières de l'entreprise Merz Pharmaceuticals
Nos références clients
Ils ont consulté nos études
Découvrir les avis (+500)
Malcolm Vincent
Astoria Finance
Gregoire de Castelnau
Stags Participations
Timothé Huignard
PWC
Paul-Alexis Kebabtchieff
BCG
Aymeric Granet
Publicis Consultant
interviews & Cas clients
Toutes les interviews et cas clients (45)
